Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

Objective: Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR) foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldenström, Jesper, Färkkilä, Martti, Rembeck, Karolina, Norkrans, Gunnar, Langeland, Nina, Mørch, Kristine, Pedersen, Court, Rauning Buhl, Mads, Nieminen, Urpo, Nuutinen, Hannu, Alsiö, Åsa, Holmström, Lars, Jungnelius, Rolf, Lund, Katarina, Rubensson, Anders, Torell, Erik, Westin, Johan, Lagging, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2016
Materias:
Liver and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732462/
https://www.ncbi.nlm.nih.gov/pubmed/26418670
http://dx.doi.org/10.3109/00365521.2015.1087588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732462/
https://www.ncbi.nlm.nih.gov/pubmed/26418670
http://dx.doi.org/10.3109/00365521.2015.1087588

Ejemplares similares